Brentuximab vedotin plus chemotherapy for stage III/IV classical Hodgkin lymphoma: 4-year update of the ECHELON-1 study Radford, J., Bartlett, N., Straus, D., Dlugosz-Danecka, M., Alekseev, S., Illes, A., Lech-Maranda, E., Feldman, T., Smolewski, P., Savage, K., Walewski, J., Ramchandren, R., Zinzani, P. L., Hutchings, M., Connors, J., Munoz, J., Kim, W. S., Advani, R., Ansell, S., Younes, A., Gallamini, A., Miao, H., Liu, R., Fenton, K., Forero-Torres, A., Picardi, M. WILEY. 2020: 101–2

View details for Web of Science ID 000528597400137